Clinical benefits in the treatment of endometriosis and uterine myoma with the suppression of GnRH and the use of selective progesterone receptor modulators [34] allow us to suggest that approaches that are not based on complete suppression of the GnRH axis have clear clinical significance. The gene discussed is GNRH1; the disease is endometriosis.